Fueling Life
Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing first-in-class drug candidates. Our lead product candidate, trans sodium crocetinate (TSC), is a synthetic small-molecule that uses a novel method of action to enhance oxygen diffusion to oxygen-deprived (hypoxic) tissue. We believe that TSC has the potential to treat millions of patients annually for conditions in which hypoxia is present, including cardiovascular and respiratory diseases, stroke, cancer and other serious conditions with unmet medical needs.
A Phase 1 study of TSC in healthy subjects was successfully completed in 2007. The company is now initiating Phase 2 proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Annual markets for these conditions are over a billion dollars each in the United States alone.
Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia.
April 8, 2008
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled “Bipolar Trans Carotenoid Salts and Their Uses”, for its
CHARLOTTESVILLE, VA – Tuesday, April 8, 2008 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing drugs utilizing a novel method of action that enhances oxygen diffusion, today announced that it has been granted U.S. patent no. 7,351,844 entitled “Bipolar Trans Carotenoid Salts and Their Uses.” This patent includes claims to a family of first-in-class […]
December 21, 2007
Co-Inventor of Amgen’s Aranesp® Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals’ First-in-Class Oxygen Enhancing Therapeutics
CHARLOTTESVILLE, VA – December 21, 2007 – Diffusion Pharmaceuticals LLC, a clinical stage drug-development company commercializing first-in-class drugs utilizing a novel mechanism of action that enhances oxygen diffusion, today announced that one of its key advisors, Mr. Thomas Byrne, was recently recognized as a co-inventor of the underlying technology of Amgen’s blockbuster drug […]
September 28, 2007
Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
CHARLOTTESVILLE, VA – September 28, 2007 – Diffusion Pharmaceuticals LLC, a clinical-stage drug development company commercializing first-in-class drugs utilizing a novel mechanism of action that enhances oxygen diffusion, today announced the results of a Phase I safety trial of its lead drug candidate, trans sodium crocetinate (TSC). In addition, the company announced the […]
